{"schema_version":"secwatch.filing_event.v1","accession":"0001378325-25-000039","form_type":"8-K","ticker":"CV","cik":"0001378325","company_name":"CapsoVision, Inc","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.261909+00:00","generated_at":"2026-05-16T20:13:02.124506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CapsoVision Q3 revenue $3.5M (+19% YoY); FDA submission for pancreatic cancer capsule","bullets":["Revenue $3.5M (+19% YoY); new accounts up 31%; CapsoCam Plus used by 151k patients.","Gross profit $1.9M (+16%); gross margin 54% vs 56% in Q3 2024.","Operating expenses $9.9M (+$2.5M) driven by Canon CMOS development and public company costs.","Cash $17.8M; July 2025 IPO net proceeds $23.4M.","Submitted FDA Breakthrough Device Designation for early-stage pancreatic cancer detection; David Garcia appointed SVP Finance."],"urls":{"canonical":"https://secwatch.observer/filing/0001378325-25-000039","json":"https://secwatch.observer/filing/0001378325-25-000039.json","markdown":"https://secwatch.observer/filing/0001378325-25-000039.md","text":"https://secwatch.observer/filing/0001378325-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1378325/000137832525000039/0001378325-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1378325/000137832525000039/cv-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:13:02.124506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}